I-Mab Announces CMO Transition, Interim Successor Named

I-Mab Adr (IMAB) has released an update.

I-Mab has announced the resignation of their Chief Medical Officer Dr. John Hayslip, who is departing to pursue new opportunities and whose exit is not due to internal conflicts. In the interim, the company has engaged Dr. Louie Naumovski, a seasoned professional with over 30 years in the biopharmaceutical industry, specializing in oncology drug development. The search for a permanent successor is currently underway.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.